Anavex Life Sciences Corp (AVXL)

[Hoskuld]

Canes, this is true when a therapy has marginal value. Amarin's strategy works in the US but the EU needs real ROI for them to move forward. Where 2-73 has real efficacy and no safety issues, it should see more rapid and universal adoption - especially if there is an EU pharmaceutical partner to run the process.